Switch theme
Sign up to access all valuation multiples
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
1950
109
LTM Revenue $4.2M
LTM EBITDA n/a
$25.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PharmX Technologies has a last 12-month revenue of $4.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, PharmX Technologies achieved revenue of $3.8M and an EBITDA of $0.2M.
PharmX Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PharmX Technologies valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $7.5M | $3.8M | XXX | XXX | XXX |
| Gross Profit | n/a | $6.6M | XXX | XXX | XXX |
| Gross Margin | NaN% | 175% | XXX | XXX | XXX |
| EBITDA | $1.6M | $0.2M | XXX | XXX | XXX |
| EBITDA Margin | 21% | 5% | XXX | XXX | XXX |
| Net Profit | n/a | $0.2M | XXX | XXX | XXX |
| Net Margin | NaN% | 4% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PharmX Technologies's stock price is AUD 0 (or $0).
PharmX Technologies has current market cap of AUD 44.9M (or $28.2M), and EV of AUD 40.6M (or $25.5M).
See PharmX Technologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.5M | $28.2M | XXX | XXX | XXX | XXX | $0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PharmX Technologies has market cap of $28.2M and EV of $25.5M.
PharmX Technologies's trades at 6.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate PharmX Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PharmX Technologies and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $25.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPharmX Technologies's NTM/LTM revenue growth is -100%
PharmX Technologies's revenue per employee for the last fiscal year averaged $35K, while opex per employee averaged $34K for the same period.
Over next 12 months, PharmX Technologies's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PharmX Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PharmX Technologies and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -50% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -87% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $35K | XXX | XXX | XXX | XXX |
| Opex per Employee | $34K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 47% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | -1% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 98% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmX Technologies acquired XXX companies to date.
Last acquisition by PharmX Technologies was XXXXXXXX, XXXXX XXXXX XXXXXX . PharmX Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PharmX Technologies founded? | PharmX Technologies was founded in 1950. |
| Where is PharmX Technologies headquartered? | PharmX Technologies is headquartered in Australia. |
| How many employees does PharmX Technologies have? | As of today, PharmX Technologies has 109 employees. |
| Is PharmX Technologies publicy listed? | Yes, PharmX Technologies is a public company listed on ASX. |
| What is the stock symbol of PharmX Technologies? | PharmX Technologies trades under PHX ticker. |
| When did PharmX Technologies go public? | PharmX Technologies went public in 1973. |
| Who are competitors of PharmX Technologies? | Similar companies to PharmX Technologies include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of PharmX Technologies? | PharmX Technologies's current market cap is $28.2M |
| What is the current revenue of PharmX Technologies? | PharmX Technologies's last 12-month revenue is $4.2M. |
| What is the current EV/Revenue multiple of PharmX Technologies? | Current revenue multiple of PharmX Technologies is 6.1x. |
| What is the current revenue growth of PharmX Technologies? | PharmX Technologies revenue growth between 2023 and 2024 was -50%. |
| Is PharmX Technologies profitable? | Yes, PharmX Technologies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
